PharmiWeb.com - Global Pharma News & Resources

Press Releases - 2025-03-31

Date Title Company
31-Mar-2025 1933 Industries Reports Second Quarter 2025 Financial Results ACCESS NewsWire
31-Mar-2025 Verisante Technology, Inc. Announces Termination of Proposed RTO with SunRegen Healthcare AG ACCESS NewsWire
31-Mar-2025 AAVantgarde and TIGEM Publish Groundbreaking Research in Science Advances AAVantgarde Bio
31-Mar-2025 OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod OKYO Pharma
31-Mar-2025 IMFINZI® (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer AstraZeneca
31-Mar-2025 Lynred launches two Advanced Thermal Imaging (ATI) modules to make cooled infrared sensing easier to use Andrew Lloyd Associates
31-Mar-2025 Healthcare Revenue Cycle Management Market is Expected to Reach ~11–12% CAGR by 2027 Medi-Tech Insights
31-Mar-2025 APONTIS PHARMA with significant sales and earnings increase in 2024 financial year – squeeze-out and merger planned APONTIS PHARMA AG
31-Mar-2025 Glidewell Partners With Digital Arches to Streamline All-on-X Workflows ACCESS NewsWire
31-Mar-2025 Global Animal Health Market Size, Share and Growth is Expand at 8-9% CAGR by 2029 Medi-Tech Insights
31-Mar-2025 Clinical Trials Market Expands at 6-7% CAGR: Driving Breakthroughs in Medical Research Medi-Tech Insights
31-Mar-2025 Pharmacy Automation Market to Expand at 8.5% CAGR | Innovations Reshaping the Industry Medi-Tech Insights
31-Mar-2025 Bioanalytical Services Market Outlook: Set for Double-Digit CAGR Growth by 2027 Medi-Tech Insights
31-Mar-2025 Global Home Healthcare Services Market Set to Grow at ~8–10% CAGR by 2029 Medi-Tech Insights
31-Mar-2025 RYBREVANT®▼ (amivantamab) plus LAZCLUZE®▼ (lazertinib) demonstrates significant overall survival benefit in patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations versus osimertinib Johnson & Johnson
31-Mar-2025 Following a planned interim analysis in the PROCEED trial Lundbeck expands the dose finding to intravenous administration of Lu AG09222 in migraine prevention Lundbeck
31-Mar-2025 MAJOR BREAKTHROUGH IN RESPIRATORY DIAGNOSTICS SET TO TRANSFORM NHS LUNG CARE TidalSense
31-Mar-2025 Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors Sanofi
31-Mar-2025 VIVA Pediatric Healthcare Expands With Acquisition of Two PPECCs in Longview and Lubbock, Texas ACCESS NewsWire
31-Mar-2025 Abbott Receives CE Mark for its Volt™ Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms Abbott